UPDATE: Abbott Reports 4 Percent Dx Growth on Strong Core Lab, Point of Care Sales | GenomeWeb

This article has been updated to include comments from Abbott's earnings call.

NEW YORK (GenomeWeb) – Abbott reported Wednesday morning that second quarter sales in its Diagnostics business grew 4 percent year over year, driven in part by a 12 percent year-over-year increase in point-of-care diagnostic sales.

For the three months ended June 30, Abbott reported overall Q2 revenues of $5.33 billion, up 3 percent from $5.17 billion in Q2 last year. The company beat the consensus Wall Street estimate of $5.24 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

Dec
06
Sponsored by
Natera

This webinar will discuss a partnership model for noninvasive prenatal testing that enabled LifeLabs Genetics, a genetic testing lab based in Toronto, Ontario, to implement NIPT in house.